<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-13</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-13</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>52</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>3</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
åˆ©ç”¨å¾ªç¯è½¬å½•ç»„é¢„æµ‹è†€èƒ±ç™Œå…ç–«æ²»ç–—ååº”ï¼ˆGSE307931ï¼‰ï¼› oHSVä»‹å¯¼JAG1é˜»æ–­è¯±å¯¼èƒ¶è´¨ç˜¤è¡°è€ç›¸å…³åˆ†æ³Œè¡¨å‹ï¼Œå¢å¼ºå·¨å™¬ç»†èƒæ´»åŒ–å¹¶å¯¹è¥¿å¦¥æ˜”å•æŠ—æ•æ„Ÿï¼ˆGSE304030, GSE303833, GSE303830ï¼‰ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«ä¸æ²»ç–—</strong>ï¼šæ¢ç´¢å…ç–«æ£€æŸ¥ç‚¹é˜»æ–­ç–—æ³•åœ¨è†€èƒ±ç™Œä¸­çš„å“åº”æœºåˆ¶ï¼›ç ”ç©¶KRASçªå˜ç»“ç›´è‚ ç™Œçš„è¥å…»å“åº”ï¼›å¼€å‘é¶å‘L1CAMçš„æŠ—ä½“å¶è”è¯ç‰©æ²»ç–—è½¬ç§»æ€§ç™Œç—‡ï¼›æ­ç¤ºCD38åœ¨CNSç‚ç—‡ä¸­çš„ä½œç”¨ã€‚<br />
*   <strong>ç™Œç—‡ä¿¡å·é€šè·¯ä¸è°ƒæ§</strong>ï¼šè§£æTRMT112åœ¨ä¸‰é˜´æ€§ä¹³è…ºç™Œç”Ÿé•¿è½¬ç§»ä¸­çš„ä½œç”¨ï¼›ç ”ç©¶APCå¯¹SETD8çš„è°ƒæ§ä»¥æŠ‘åˆ¶ç»“ç›´è‚ ç™Œï¼›æ¢ç©¶RXRä»‹å¯¼çš„è½¬å½•ç»„å’ŒæŸ“è‰²è´¨é‡å¡‘åœ¨é˜¿å°”èŒ¨æµ·é»˜ç—…æ¨¡å‹ä¸­çš„ä½œç”¨ã€‚<br />
*   <strong>ç»†èƒä»£è°¢ä¸å¾®ç¯å¢ƒ</strong>ï¼šé˜æ˜è„‚è‚ªé…¸ä»£è°¢å¯¹å£è…”é³çŠ¶ç»†èƒç™Œè½¬ç§»çš„å½±å“ï¼›ç ”ç©¶RASæŠ‘åˆ¶å‰‚å¯¹ç»“ç›´è‚ ç™Œç»†èƒè½¬å½•ç»„çš„å½±å“ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   æ•´åˆå¤šç»„å­¦ï¼ˆè½¬å½•ç»„ã€è¡¨è§‚é—ä¼ ã€TCRå…‹éš†æ€§ï¼‰åˆ†ææ…¢æ€§GVHDä¸­CD4+ Tmç»†èƒçš„æœºåˆ¶ï¼ˆGSE263812, GSE263811, GSE263810, GSE263813ï¼‰ã€‚<br />
*   å•ç»†èƒæµ‹åºæŠ€æœ¯åº”ç”¨äºè„‘æŸä¼¤ï¼ˆGSE292715ï¼‰ã€è§†ç½‘è†œå¾®è§‚æ¿€æ´»å¯é€†æ€§ï¼ˆGSE285564ï¼‰ã€ä»¥åŠå¤§é¼ è‚ºéƒ¨æ‰‹æœ¯å“åº”ï¼ˆGSE312833, GSE311758ï¼‰ç­‰ç ”ç©¶ã€‚</p>
<h3>ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Bioconductor æ‹›å‹Ÿ Outreachy 2025 å¹´å®ä¹ ç”Ÿï¼Œä¸ºåˆå­¦è€…æä¾›å¼€æºæŠ€æœ¯èŒä¸šå‘å±•æœºä¼šã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>ç”Ÿç‰©ä¿¡æ¯å­¦å¼€æºé¡¹ç›®è´¡çŒ®</strong>ï¼šé€šè¿‡å‚ä¸ Bioconductor ç­‰å¼€æºé¡¹ç›®ï¼Œå­¦ä¹ å’Œå®è·µç”Ÿç‰©ä¿¡æ¯å­¦å·¥å…·å¼€å‘ä¸ç»´æŠ¤ã€‚<br />
*   <strong>ç¤¾åŒºåä½œä¸æŠ€èƒ½æå‡</strong>ï¼šèå…¥å…¨çƒå¼€æºç¤¾åŒºï¼Œä¸å…¶ä»–å¼€å‘è€…åä½œï¼Œæå‡æŠ€æœ¯èƒ½åŠ›å’ŒèŒä¸šç´ å…»ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å¼€æºä»£ç è®¿é—®ä¸å­¦ä¹ </strong>ï¼šæä¾›ç›´æ¥æ¥è§¦å’Œå­¦ä¹ å…ˆè¿›ç”Ÿç‰©ä¿¡æ¯å­¦æºä»£ç çš„æœºä¼šã€‚<br />
*   <strong>å…¨çƒç¤¾åŒºæ”¯æŒ</strong>ï¼šè·å¾—æ¥è‡ªä¸–ç•Œå„åœ°ç»éªŒä¸°å¯Œçš„å¼€å‘è€…çš„æŒ‡å¯¼å’Œæ”¯æŒã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ä¸€ç§æ–°å‹åŸºå› ç¼–è¾‘CAR-Tç»†èƒç–—æ³•åœ¨æ²»ç–—ä¾µè¢­æ€§Tç»†èƒç™½è¡€ç—…æ–¹é¢å–å¾—é‡å¤§çªç ´ï¼›ç¥ç»æŸä¼¤å¯å¼•å‘å…¨èº«æ€§å…ç–«å˜åŒ–ï¼Œä¸”æ€§åˆ«ååº”å·®å¼‚æ˜¾è‘—ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ•´åˆå•ç»†èƒä¸bulk RNAæµ‹åºï¼Œè¯†åˆ«é«˜é£é™©ç»†èƒå¹¶æŒ‡å¯¼ç²¾å‡†æ²»ç–—ã€‚<br />
- å¼€å‘åŸºå› ç¼–è¾‘CAR-Tç»†èƒï¼Œæ²»ç–—Tç»†èƒæ€¥æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ã€‚<br />
- è¯„ä¼°ä¸­åº¦é¥®é…’å¯¹ç™Œç—‡é£é™©çš„å½±å“åŠä¸ªä½“å·®å¼‚ã€‚<br />
- æ¢ç©¶ç¥ç»æŸä¼¤å¦‚ä½•è¯±å¯¼å…¨èº«å…ç–«ååº”ï¼Œå¹¶åˆ†ææ€§åˆ«å·®å¼‚ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- SIDISHï¼šç»“åˆå•ç»†èƒä¸bulk RNAæµ‹åºï¼Œæå‡ä¸´åºŠé¢„æµ‹å’Œé¶å‘æ²»ç–—èƒ½åŠ›ã€‚<br />
- ç¢±åŸºç¼–è¾‘å…ç–«ç»†èƒï¼šå®ç°å¯¹Tç»†èƒæ€¥æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…çš„ç²¾å‡†æ²»ç–—ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (47æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE307931 å¾ªç¯è½¬å½•ç»„åˆ†ææ£€æµ‹åŸºå› ç‰¹å¾ã€å…ç–«ç»†èƒæ´»åŒ–å’Œä¸°åº¦ï¼Œä»¥é¢„æµ‹è†€èƒ±ç™Œå…ç–«æ²»ç–—ååº”</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€regex:immuno(logy|therapy|suppression)ã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sandy Chevrier ; Corentin Richard ; Romain BoidotSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBackground. Immune Checkpoint Blockers (ICB) have revolutionized oncology by achieving durable tumor responses in advanced cancers. Nevertheless, currently approved biomarkers (PD-L1, MSI, TMB) have suboptimal positive and negative predictive values for tumor response and survival. Patients and Methods. We aimed to assess the value of RNA sequencing from circulating blood, a new type of liquid biopsy, to predict responses to ICB. We performed total paired-end RNA sequencing at 20 million reads and analyzed differential gene expression, signaling pathway activation, and immune cell abundances according to cancer outcomes. The analysis was conducted on baseline frozen whole blood samples from 164 patients prospectively enrolled in the IOPREDI study. Results. We found that some immune-related genes and signaling pathways were highly expressed in patients who achieved a durable clinical benefit. Furthermore, analyses of both progression-free survival (PFS) and overall survival (OS) confirmed significantly higher expression levels of immune-related signaling pathways in long-term survivors. Gene expression signatures capable of classifying patients based on clinical response or PFS were also identified. Interestingly, deconvolution analysis revealed a significant higher abundance of resting NK cells in patients with prolonged PFS or OS, in contrast to other cytotoxic cell types. Finally, high expression of the CST7 gene and increased abundance of naÃ¯ve B lymphocytes were associated with immune-related adverse events (irAEs). Conclusion. Total RNA sequencing from whole blood provides high-quality data to predict clinical response, survival, and occurrence of irAEs. The use of this liquid biopsy prior to immune checkpoint blockage could improve treatment efficacy and irAEs management.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307931" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>GSE313350 å¤©å†¬é…°èƒºåˆæˆé…¶å’ŒGè›‹ç™½å¶è”é›Œæ¿€ç´ å—ä½“æ˜¯KRASçªå˜å‹ç»“ç›´è‚ ç™Œä¸­è¥å…»ä¾›åº”çš„å…³é”®ååº”å› å­</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€KRAS<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Lingeng Lu ; Caroline Johnson ; Sajid KhanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSurvival differences exist in colorectal cancer (CRC) patients by sex and disease stage. However, the potential molecular mechanism(s) are not well understood. Here we show that asparagine synthetase (ASNS) and G protein-coupled estrogen receptor-1 (GPER1) are critical sensors of nutrient depletion and linked to poorer outcomes for females with CRC. In a 3D spheroid model of isogenic SW48 KRAS wild-type (WT) and G12A mutant (MT) cells grown under a restricted nutrient supply, we found that glutamine depletion inhibited cell growth in both cell types, whereas ASNS and GPER1 expression were upregulated in KRAS MT versus WT. Estradiol decreased growth in KRAS WT but had no effect on MT cells. In a clinical colon cancer cohort of The Cancer Genome Atlas, both high GPER1 and ASNS expression were associated with poorer overall survival for females only in advanced stage tumors. These results suggest KRAS MT cells have mechanisms in place that respond to decreased nutrient supply, typically observed in advanced tumors, by increasing the expression of ASNS and GPER1 to drive cell growth. Furthermore, KRAS MT cells are resistant to the protective effects of estradiol under nutrient deplete conditions. The findings indicate that GPER1 and ASNS expression in the link of nutrient supply and KRAS mutations shed additional light on the mechanisms behind sex differences in metabolism and growth in CRC and have clinical implications in the precision management of KRAS MT CRC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313350" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>GSE311963 CD38 èµ‹äºˆå±€éƒ¨æŠ—åŸç‰¹å¼‚æ€§ Foxp3+ Treg ç»†èƒåº”æ¿€è€å—æ€§ï¼Œä»è€Œå®ç°å¯¹ä¸­æ¢ç¥ç»ç³»ç»Ÿç‚ç—‡çš„åŒºå®¤åŒ–æ§åˆ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šantigenã€inflammation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Andreas Muschaweckh ; Hsin-Hsiang Chen ; Rupert Ã–llinger ; Christopher Sie ; Thomas KornSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusFoxp3-expressing regulatory T (Treg) cells protect from systemic autoimmunity. However, little is known about the significance of Treg cells in inflammation-experienced tissues. Using experimental autoimmune encephalomyelitis (EAE), we show that Treg cells accumulate and persist in the central nervous system (CNS) until long after the resolution of the bulk of the inflammatory infiltrate. CNS-specific local depletion of post-inflammatory Treg cells, but not systemic depletion of Treg cells, immediately rekindles autoimmune inflammatory flares in the CNS by residual local effector T cells. Expression of the NAD-consuming ecto-enzyme CD38 is crucial for the functional adaptation of post-inflammatory CNS Treg cells to a stressful microenvironment, in which access to IL-2 is limited. CD38 counteracts ADP-ribosylation of the IL-2R and, thus, maintains its high sensitivity to IL-2. Their fully functional high-affinity IL-2 receptor prevents the loss of tissue-resident antigen-specific Treg cells. These "stress-tolerant" CNS Treg cells impede the collapse of immune homeostasis in the CNS once acute inflammation is controlled.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311963" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE311075 TRMT112 åœ¨ä¸‰é˜´æ€§ä¹³è…ºç™Œä¸­é©±åŠ¨è‚¿ç˜¤ç”Ÿé•¿å’Œè½¬ç§»ä¿ƒè¿›ç¨‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Dongquan Chen ; Lalita Samant ; Rajeev Samant ; Amr ElhamamsySeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensRibosomal RNA Modifying Proteins (RRMPs) are integral to ribosome biogenesis, executing post-transcriptional modifications that influence translation fidelity and efficiency. Dysregulation of RRMPs has been increasingly implicated in cancer progression, yet their collective role across malignancies remains largely unexplored. Here, we performed a multi-omics analysis of 22 RRMPs across diverse cancer types using The Cancer Genome Atlas, the Molecular Taxonomy of Breast Cancer International Consortium, and additional high-throughput datasets. Our analysis revealed widespread genomic alterations and transcriptional dysregulation of RRMPs across malignancies, with distinct expression patterns in breast cancer subtypes. Notably, Triple-Negative Breast Cancer (TNBC) exhibited the highest RRMPs enrichment, which correlated with increased genomic instability including elevated tumor mutational burden and aneuploidy scores, and poor survival outcomes. Among the RRMPs, tRNA methyltransferase activator subunit 11-2 (TRMT112) emerged as a key regulator of tumor progression. Functional assays demonstrated that TRMT112 knockdown in TNBC cells significantly reduced proliferation, migration, invasion, and metastatic potential, whereas its overexpression enhanced these tumorigenic properties. Polysome profiling and RNA sequencing of actively translated transcripts revealed that TRMT112 reprograms the translational landscape by promoting pro-metastatic and stromal remodeling pathways while suppressing immune-related processes. In vivo studies using an orthotopic breast cancer model further confirmed that TRMT112 depletion impairs tumor growth and reduces metastatic burden. Collectively, our findings establish RRMPs as critical modulators of cancer progression and identify TRMT112 as a key driver of aggressive phenotypes in TNBC. The dysregulation of TRMT112 across breast cancer subtypes highlights its potential as both a prognostic biomarker and a therapeutic target. These insights provide a mechanistic foundation for future interventions aimed at targeting TRMT112-driven translational programs in aggressive breast cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311075" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE304030 oHSVä»‹å¯¼çš„JAG1é˜»æ–­è¯±å¯¼èƒ¶è´¨ç˜¤è¡°è€ç›¸å…³åˆ†æ³Œè¡¨å‹ï¼Œä»è€Œå¢å¼ºå·¨å™¬ç»†èƒæ´»åŒ–å¹¶æé«˜å…¶å¯¹è¥¿å¦¥æ˜”å•æŠ—ä»‹å¯¼çš„è¡°è€ç»†èƒæ¸…é™¤çš„æ•æ„Ÿæ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmacrophageã€glioma<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kimberly A Rivera-Caraballo ; Tae Jin Lee ; Arnoneel Sinha ; Marco Orecchioni ; Karina Vazquez-Arreguin ; Shilpa Sharma ; Kimya Jones ; Upasana Sahu ; Sara A Murphy ; Bangxing Hong ; Ravindra Kolhe ; Ashok Sharma ; Balveen KaurSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusOncolytic HSV-1 (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical models. In the clinic, upregulation of JAG1 gene expression was observed in recurrent high-grade glioma patients treated with CAN-3110. Since JAG1 is expressed on both glioma cells and tumor-associated macrophages (TAMs), and its expression correlated with a worse prognosis, we engineered a JAG1-antagonizing oHSV (OncoD-0J1) and interrogated its impact on the tumor and myeloid TME. OncoD-0J1 antagonized JAG1-mediated Notch signaling and had a significant therapeutic advantage in vivo, which relied on Notch signature in tumor cells. Kinome profiling revealed that OncoD-0J1 treatment suppressed CDK1, resulting in a G2/M cell cycle checkpoint as seen by cell cycle analysis. Cell cycle arrest led to senescence and correlated with increased reactive oxygen species, p62 accumulation, autophagosome accumulation, and senescence-associated beta-galactosidase activity. This resulted in increased production of inflammatory chemokines and DAMPs such as IL-1Î² and extracellular ATP. RNA sequencing of murine macrophages co-cultured with infected human tumor cells showed enrichment of chemotactic and pro-inflammatory pathways as well as increased Fc receptor activation following OncoD-0J1 infection. Single-cell RNA sequencing and flow cytometric analysis of F4/80+ cells isolated from infected tumors showed a shift from tumor-supporting TAMs to inflammatory macrophages upon OncoD-0J1 treatment. Senescent cells showed heightened EGFR activation as a mechanism to escape death, which created a unique vulnerability for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic response of OncoD-0J1 as a monotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304030" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE303833 oHSVä»‹å¯¼çš„JAG1é˜»æ–­è¯±å¯¼èƒ¶è´¨ç˜¤è¡°è€ç›¸å…³åˆ†æ³Œè¡¨å‹ï¼Œä»è€Œå¢å¼ºå·¨å™¬ç»†èƒæ´»åŒ–å¹¶æé«˜å¯¹è¥¿å¦¥æ˜”å•æŠ—ä»‹å¯¼çš„è¡°è€ç»†èƒæ¸…é™¤çš„æ•æ„Ÿæ€§ III</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmacrophageã€glioma<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kimberly A Rivera-Caraballo ; Tae Jin Lee ; Arnoneel Sinha ; Marco Orecchioni ; Karina Vazquez-Arreguin ; Shilpa Sharma ; Kimya Jones ; Upasana Sahu ; Sara A Murphy ; Bangxing Hong ; Ravindra Kolhe ; Ashok Sharma ; Balveen KaurSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusOncolytic HSV-1 (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical models. In the clinic, upregulation of JAG1 gene expression was observed in recurrent high-grade glioma patients treated with CAN-3110. Since JAG1 is expressed on both glioma cells and tumor-associated macrophages (TAMs), and its expression correlated with a worse prognosis, we engineered a JAG1-antagonizing oHSV (OncoD-0J1) and interrogated its impact on the tumor and myeloid TME. OncoD-0J1 antagonized JAG1-mediated Notch signaling and had a significant therapeutic advantage in vivo, which relied on Notch signature in tumor cells. Kinome profiling revealed that OncoD-0J1 treatment suppressed CDK1, resulting in a G2/M cell cycle checkpoint as seen by cell cycle analysis. Cell cycle arrest led to senescence and correlated with increased reactive oxygen species, p62 accumulation, autophagosome accumulation, and senescence-associated beta-galactosidase activity. This resulted in increased production of inflammatory chemokines and DAMPs such as IL-1Î² and extracellular ATP. RNA sequencing of murine macrophages co-cultured with infected human tumor cells showed enrichment of chemotactic and pro-inflammatory pathways as well as increased Fc receptor activation following OncoD-0J1 infection. Single-cell RNA sequencing and flow cytometric analysis of F4/80+ cells isolated from infected tumors showed a shift from tumor-supporting TAMs to inflammatory macrophages upon OncoD-0J1 treatment. Senescent cells showed heightened EGFR activation as a mechanism to escape death, which created a unique vulnerability for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic response of OncoD-0J1 as a monotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303833" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE303830 oHSVä»‹å¯¼çš„JAG1é˜»æ–­è¯±å¯¼èƒ¶è´¨ç˜¤è¡°è€ç›¸å…³åˆ†æ³Œè¡¨å‹ï¼Œä»è€Œå¢åŠ å·¨å™¬ç»†èƒæ´»åŒ–å¹¶å¢å¼ºå¯¹è¥¿å¦¥æ˜”å•æŠ—ä»‹å¯¼çš„è¡°è€ç»†èƒæ¸…é™¤çš„æ•æ„Ÿæ€§ I</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmacrophageã€glioma<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kimberly A Rivera-Caraballo ; Tae Jin Lee ; Arnoneel Sinha ; Marco Orecchioni ; Karina Vazquez-Arreguin ; Shilpa Sharma ; Kimya Jones ; Upasana Sahu ; Sara A Murphy ; Bangxing Hong ; Ravindra Kolhe ; Ashok Sharma ; Balveen KaurSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensOncolytic HSV-1 (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical models. In the clinic, upregulation of JAG1 gene expression was observed in recurrent high-grade glioma patients treated with CAN-3110. Since JAG1 is expressed on both glioma cells and tumor-associated macrophages (TAMs), and its expression correlated with a worse prognosis, we engineered a JAG1-antagonizing oHSV (OncoD-0J1) and interrogated its impact on the tumor and myeloid TME. OncoD-0J1 antagonized JAG1-mediated Notch signaling and had a significant therapeutic advantage in vivo, which relied on Notch signature in tumor cells. Kinome profiling revealed that OncoD-0J1 treatment suppressed CDK1, resulting in a G2/M cell cycle checkpoint as seen by cell cycle analysis. Cell cycle arrest led to senescence and correlated with increased reactive oxygen species, p62 accumulation, autophagosome accumulation, and senescence-associated beta-galactosidase activity. This resulted in increased production of inflammatory chemokines and DAMPs such as IL-1Î² and extracellular ATP. RNA sequencing of murine macrophages co-cultured with infected human tumor cells showed enrichment of chemotactic and pro-inflammatory pathways as well as increased Fc receptor activation following OncoD-0J1 infection. Single-cell RNA sequencing and flow cytometric analysis of F4/80+ cells isolated from infected tumors showed a shift from tumor-supporting TAMs to inflammatory macrophages upon OncoD-0J1 treatment. Senescent cells showed heightened EGFR activation as a mechanism to escape death, which created a unique vulnerability for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic response of OncoD-0J1 as a monotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303830" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE263812 å°é¼ æ…¢æ€§ GVHD æœŸé—´è‚è„å’Œè‚ºä¸­ CD4âº Tm äºšç¾¤çš„æ•´åˆè½¬å½•ç»„å­¦ã€è¡¨è§‚é—ä¼ å­¦å’Œ TCR å…‹éš†æ€§åˆ†æ [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šscRNAã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Defu Zeng ; Xiwei Wu ; Xiaohui Kong ; Hyejin ChoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPathogenic CD4+ T cells perpetuate chronic tissue inflammation, but mechanisms remain largely undefined. Here, with transcriptome, epigenome, and clonal analysis, we compared CD4+Tm subsets among the liver and lung in the No GVHD and cGVHD recipients. Four CD4+Tm subsets identified with Ly108 versus CD69 expression were compared.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263812" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE263811 å°é¼ æ…¢æ€§ GVHD æœŸé—´è‚è„å’Œè‚ºä¸­ CD4âº Tm äºšç¾¤çš„è½¬å½•ç»„å­¦ã€è¡¨è§‚é—ä¼ å­¦å’Œ TCR å…‹éš†æ€§ç»¼åˆåˆ†æ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Defu Zeng ; Xiwei Wu ; Xiaohui Kong ; Hyejin ChoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPathogenic CD4+ T cells perpetuate chronic tissue inflammation, but mechanisms remain largely undefined. Here, with transcriptome, epigenome, and clonal analysis, we compared CD4+Tm subsets among the liver and lung in the No GVHD and cGVHD recipients. Four CD4+Tm subsets identified with Ly108 versus CD69 expression were compared<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263811" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE263810 å°é¼ æ…¢æ€§ GVHD æœŸé—´è‚è„å’Œè‚ºä¸­ CD4âº Tm äºšç¾¤çš„æ•´åˆè½¬å½•ç»„å­¦ã€è¡¨è§‚é—ä¼ å­¦å’Œ TCR å…‹éš†æ€§åˆ†æ [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šATAC-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Defu Zeng ; Xiwei Wu ; Xiaohui Kong ; Hyejin ChoSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusPathogenic CD4+ T cells perpetuate chronic tissue inflammation, but mechanisms remain largely undefined. Here, with transcriptome, epigenome, and clonal analysis, we compared CD4+Tm subsets among the liver and lung in the No GVHD and cGVHD recipients. Four CD4+Tm subsets identified with Ly108 versus CD69 expression were compared.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263810" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 37 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡ (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>Outreachy 2025å¹´6æœˆ Bioconductorå®ä¹ ç”Ÿ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šBioconductor<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šIntroduction To a beginner, open source can be one of the best pathways into a fulfilling tech career. It not only provides access to source codes but also connects you with a global community of people from diverse backgrounds and skill sets. ... Continue reading: Outreachy June 2025 Interns with Bioconductor<br />
- ğŸ”— <a href="https://www.r-bloggers.com/2025/12/outreachy-june-2025-interns-with-bioconductor/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>SIDISHâ€”â€”å°†å•ç»†èƒä¿¡æ¯ä¸æ‰¹é‡RNAæµ‹åºç›¸ç»“åˆï¼Œä»¥è¯†åˆ«é«˜é£é™©ç»†èƒå¹¶æŒ‡å¯¼ç²¾å‡†æ²»ç–—</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSIDISH merges single cell data with bulk RNA sequencing to identify high risk cells, improve clinical prediction and reveal therapeutic targets<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/sidish-integrating-single-cell-insights-with-bulk-rna-sequencing-to-identify-high-risk-cells-and-guide-precision-therapeutics/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>åŸºå› ç¼–è¾‘çš„CAR-Tç»†èƒå¯æ¸…é™¤ä¾µè¢­æ€§Tç»†èƒç™½è¡€ç—…</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemia<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely rewriting tiny sections of DNA, scientists at UCL and Great Ormond Street Hospital created universal CAR T-cells capable of targeting the cancer without harming themselvesâ€”a long-standing challenge in T-cellâ€“based therapies. Early trial results show deep, long-lasting remissions, including in patients who had exhausted standard treatment options.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251211040438.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>å³ä½¿æ˜¯é€‚é‡é¥®é…’ï¼Œå…¶æ‚£ç™Œé£é™©ä¹Ÿæ¯”ä½ æƒ³è±¡çš„è¦é«˜ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers found that both how often and how much someone drinks significantly shape their cancer risk, even at moderate levels. Vulnerability varies across groups, with genetics, socioeconomic status, obesity, and lifestyle behaviors amplifying harm. The review also uncovered gender differences, beverage-specific risks, and biological pathways that intensify cancer development.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251211100612.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ç¥ç»æŸä¼¤ä¼šå¼•å‘å…¨èº«éšåŒ¿çš„å…ç–«å˜åŒ–ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers discovered that nerve injuries can alter the immune system throughout the body, and males and females react very differently. Male mice showed strong inflammatory responses, while females showed none, yet both transmitted pain-inducing signals through their blood. These findings reveal previously unknown pathways driving pain, especially in females. The work points toward new opportunities for personalized chronic pain therapies.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251211100623.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>10</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>7</td>
</tr>
<tr>
<td>sequencing</td>
<td>6</td>
</tr>
<tr>
<td>single-cell</td>
<td>4</td>
</tr>
<tr>
<td>epigenetic</td>
<td>4</td>
</tr>
<tr>
<td>transcriptome</td>
<td>4</td>
</tr>
<tr>
<td>macrophage</td>
<td>3</td>
</tr>
<tr>
<td>glioma</td>
<td>3</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>3</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>tumor</td>
<td>2</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>HLA</td>
<td>2</td>
</tr>
<tr>
<td>KRAS</td>
<td>1</td>
</tr>
<tr>
<td>antigen</td>
<td>1</td>
</tr>
<tr>
<td>inflammation</td>
<td>1</td>
</tr>
<tr>
<td>leukemia</td>
<td>1</td>
</tr>
<tr>
<td>scRNA</td>
<td>1</td>
</tr>
<tr>
<td>regex:intestin(e</td>
<td>al)</td>
</tr>
<tr>
<td>lymphoma</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (37æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292715" target="_blank" rel="noopener noreferrer">GSE292715 å•ç»†èƒæµ‹åºæ­ç¤ºè½»åº¦åˆ›ä¼¤æ€§è„‘æŸä¼¤å¯¹æµ·é©¬ä½“çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312946" target="_blank" rel="noopener noreferrer">GSE312946 åŸºè´¨ç»†èƒå¯¹è„‚è‚ªé…¸çš„ä»£è°¢é€‚åº”é©±åŠ¨å£è…”é³çŠ¶ç»†èƒç™Œçš„è½¬ç§»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307811" target="_blank" rel="noopener noreferrer">GSE307811 å¼€å‘é¶å‘L1CAMçš„æŠ—ä½“è¯ç‰©å¶è”ç‰©ä»¥æ²»ç–—è½¬ç§»æ€§ç™Œç—‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287188" target="_blank" rel="noopener noreferrer">GSE287188 æ´»æ€§çŠ¶æ€ RAS æŠ‘åˆ¶å¯¹ç»“ç›´è‚ ç™Œç»†èƒè½¬å½•ç»„çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285564" target="_blank" rel="noopener noreferrer">GSE285564 å¯¹è§†ç½‘è†œä¸­é«“ç³»ç»†èƒåœ¨ç§»æ¤äººç±»å¹²ç»†èƒè¡ç”Ÿç¥ç»å…ƒå’Œçœ¼æŸä¼¤åè¿›è¡Œå•ç»†èƒè½¬å½•ç»„æ¯”è¾ƒï¼Œæ­ç¤ºäº†å°èƒ¶è´¨ç»†èƒæ´»åŒ–çš„å¯é€†æ€§ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313053" target="_blank" rel="noopener noreferrer">GSE313053 APC åè°ƒ GSK3 å¯¹ SETD8 çš„ç£·é…¸åŒ–ä»¥æŠ‘åˆ¶ç»“ç›´è‚ ç™Œ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312833" target="_blank" rel="noopener noreferrer">GSE312833 å¤§é¼ è‚ºç»„ç»‡Glennæ‰‹æœ¯æˆ–å‡æ‰‹æœ¯åçš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311758" target="_blank" rel="noopener noreferrer">GSE311758 æ‰¹é‡ RNA æµ‹åºï¼šGlenn æ‰‹æœ¯æˆ–å‡æ‰‹æœ¯ä»¥åŠé¥®é£Ÿè°ƒæ•´å CD31 åˆ†é€‰çš„è‚ºç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308672" target="_blank" rel="noopener noreferrer">GSE308672 åˆ©ç”¨å•æ ¸è½¬å½•ç»„å­¦è§£ææ‹Ÿå—èŠ¥æ ¹ä¸­ç¦»æ•£çš„ã€ç»†èƒç‰¹å¼‚æ€§çš„ç¼ºæ°§ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306023" target="_blank" rel="noopener noreferrer">GSE306023 CD8 T ç»†èƒå— HLA-B<em>57 å’Œ HLA-E</em>01 äº¤å‰é™åˆ¶ï¼Œè¯†åˆ« HIV Gag å…·æœ‰ä¸åŒçš„åŠŸèƒ½ç‰¹å¾ [æ•°æ®é›† 2]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306022" target="_blank" rel="noopener noreferrer">GSE306022 CD8 T ç»†èƒå— HLA-B<em>57 å’Œ HLA-E</em>01 äº¤å‰é™åˆ¶ï¼Œè¯†åˆ« HIV Gag å…·æœ‰ä¸åŒçš„åŠŸèƒ½ç‰¹å¾ [æ•°æ®é›† 1]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289039" target="_blank" rel="noopener noreferrer">GSE289039 RXRä»‹å¯¼çš„APPå°é¼ è„‘è½¬å½•å’ŒæŸ“è‰²è´¨ç»“æ„é‡å¡‘ï¼šæ¥è‡ªæ•´åˆçš„å•ç»†èƒRNAå’ŒATACåˆ†æçš„å¯ç¤º</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286174" target="_blank" rel="noopener noreferrer">GSE286174 ç³»ç»Ÿæ–¹æ³•æ­ç¤º SMARCD3 è°ƒæ§å­é©±åŠ¨ä¾ç»´è«å¸è€è¯ä¹³è…ºç™Œç»†èƒçš„æ›¿ä»£ç”Ÿé•¿ä¿¡å·ä¼ å¯¼å’Œå¯¹ MEK æŠ‘åˆ¶å‰‚çš„æ•æ„Ÿæ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283906" target="_blank" rel="noopener noreferrer">GSE283906 RXRä»‹å¯¼çš„APPå°é¼ è„‘è½¬å½•å’ŒæŸ“è‰²è´¨å›¾è°±é‡å¡‘ï¼šæ¥è‡ªæ•´åˆçš„å•ç»†èƒRNAå’ŒATACåˆ†æçš„å¯ç¤º</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263813" target="_blank" rel="noopener noreferrer">GSE263813 å°é¼ æ…¢æ€§ GVHD æœŸé—´è‚è„å’Œè‚ºä¸­ CD4âº Tm äºšç¾¤çš„æ•´åˆè½¬å½•ç»„å­¦ã€è¡¨è§‚é—ä¼ å­¦å’Œ TCR å…‹éš†æ€§åˆ†æ [scTCR-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313474" target="_blank" rel="noopener noreferrer">GSE313474 RNA-seqåˆ†æPU.1ç¼ºå¤±å¯¹CAIAå°é¼ è…¹è…”å·¨å™¬ç»†èƒä¸­RELM-a+å·¨å™¬ç»†èƒçš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313368" target="_blank" rel="noopener noreferrer">GSE313368 äººç±»è‚ é“ç±»å™¨å®˜å¯¹åˆ†æ³Œå‹å¾®ç¯å¢ƒå› å­çš„ååº”å•ç»†èƒåˆ†è¾¨ç‡è¯å…¸</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312155" target="_blank" rel="noopener noreferrer">GSE312155 è¯„ä¼°æ”¾å°„åŠ¨åŠ›ç–—æ³•åœ¨äººèƒ°è…ºç™ŒMIA PaCa-2å¼‚ç§ç§»æ¤æ¨¡å‹ä¸­çš„ç–—æ•ˆ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305165" target="_blank" rel="noopener noreferrer">GSE305165 é‡æ–°å®šä¹‰ EBV é˜³æ€§å¼¥æ¼«æ€§å¤§ B ç»†èƒæ·‹å·´ç˜¤å’Œ EBV é˜³æ€§ç»å…¸éœå¥‡é‡‘æ·‹å·´ç˜¤çš„è°±ç³»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292127" target="_blank" rel="noopener noreferrer">GSE292127ï¼šå¯¹è½»åº¦åˆ›ä¼¤æ€§è„‘æŸä¼¤åTMSB4Xæ¡ä»¶æ€§æ•²é™¤ï¼ˆCKOï¼‰å°é¼ æµ·é©¬ç¥ç»å…ƒè¿›è¡Œæ‰¹é‡RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292126" target="_blank" rel="noopener noreferrer">GSE292126 ATAC-Seq æ­ç¤ºè½»åº¦åˆ›ä¼¤æ€§è„‘æŸä¼¤å¯¹æµ·é©¬ä½“çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285889" target="_blank" rel="noopener noreferrer">GSE285889æ•´åˆè½¬å½•ç»„å­¦å’Œç½‘ç»œåˆ†ææ­ç¤ºäº†é©±åŠ¨è„‘è†œç˜¤å‘ç—…æœºåˆ¶å’Œä¸´åºŠç»“å±€çš„æ ¸å¿ƒåŸºå› </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313379" target="_blank" rel="noopener noreferrer">GSE313379 äººç±»èƒšèƒå¹²ç»†èƒä¸­å…·æœ‰æ´»æ€§çš„æŸ“è‰²è´¨åŒºåŸŸçš„å‘ç° [ChIP-Seq 2]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313377" target="_blank" rel="noopener noreferrer">GSE313377 HnRNPA2B1 é€šè¿‡ Irgm1 çš„é€‰æ‹©æ€§å‰ªæ¥è°ƒèŠ‚å·¨å™¬ç»†èƒä¸­çš„æŠ—åˆ†ææ†èŒå…ç–«ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313376" target="_blank" rel="noopener noreferrer">GSE313376 äººç±»èƒšèƒå¹²ç»†èƒä¸­å…·æœ‰æ´»æ€§çš„æŸ“è‰²è´¨åŒºåŸŸçš„å‘ç° [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312824" target="_blank" rel="noopener noreferrer">GSE312824 KMT2C ç¼ºé™·é€šè¿‡ H3K27ac ä»‹å¯¼çš„ HIPPO é€šè·¯å¤±æ´»ä¿ƒè¿›è„‘è†œç˜¤è¿›å±• [CUT&amp;Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312822" target="_blank" rel="noopener noreferrer">GSE312822 æ•´åˆè¯ä»£åŠ¨åŠ›å­¦ã€ç»„ç»‡åˆ†å¸ƒã€RNAæµ‹åºå’Œç½‘ç»œè¯ç†å­¦æ•°æ®ï¼Œç¡®å®šSTAT1å’ŒSERPINE1æ˜¯è«æ–¯å¡æ›¿æ—æ²»ç–—è‚ç—…çš„æ½œåœ¨é¶ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312820" target="_blank" rel="noopener noreferrer">GSE312820 æ–‘è¥ç´ é’ æ²»ç–—å¯¹ AGS å’Œ MKN1 èƒƒç™Œç»†èƒç³»åŸºå› è¡¨è¾¾çš„å½±å“ï¼ˆæ²»ç–—ç»„ä¸æœªæ²»ç–—ç»„ï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312810" target="_blank" rel="noopener noreferrer">GSE312810 DUS1L æ•²é™¤å’Œé‡ç”Ÿå‹ A375 äººé»‘è‰²ç´ ç˜¤ç»†èƒçš„ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298682" target="_blank" rel="noopener noreferrer">GSE298682 SCD1 æ•²ä½å¯¼è‡´ UMUC3 å’Œ SW780 ç»†èƒä¸­åŸºå› è¡¨è¾¾å·®å¼‚ï¼ˆRNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295226" target="_blank" rel="noopener noreferrer">GSE295226 CUT&amp;RUN åœ¨ SCC-25 äº²ä»£ç»†èƒå’Œ RARG æ•²é™¤ç»†èƒä¸­å®šä½ RARÎ³ ç»“åˆä½ç‚¹ä»¥åŠ H3K4 å’Œ H3K27 ä¸‰ç”²åŸºåŒ–çš„å…¨åŸºå› ç»„å˜åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293632" target="_blank" rel="noopener noreferrer">GSE293632 éœ¸æƒ EWSR1::ETS ç™ŒåŸºå› åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‡Œé©¾äºæ ¸å¿ƒè°ƒæ§å›è·¯æœºåˆ¶ä¹‹ä¸Šã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288935" target="_blank" rel="noopener noreferrer">GSE288935 äººç±»å°¿æ¶²ç»†èƒå¤–å›Šæ³¡çš„å°RNAæµ‹åºæ­ç¤ºé«˜é’ é¥®é£Ÿä¸è‚¾è„ä¿ƒç‚é€šè·¯ä¹‹é—´çš„å…³è”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271245" target="_blank" rel="noopener noreferrer">GSE271245 å”æ°ç»¼åˆå¾å‘¼å¸é“åˆèƒç—…æ¯’æ„ŸæŸ“æœŸé—´æ°”é“ä¸Šçš®JAK-STATä¿¡å·è¿‡åº¦æ¿€æ´»ä¼šæŸå®³IIIå‹å¹²æ‰°ç´ ååº”[æ‰¹é‡RNAæµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271139" target="_blank" rel="noopener noreferrer">GSE271139 å”æ°ç»¼åˆå¾å‘¼å¸é“åˆèƒç—…æ¯’æ„ŸæŸ“æœŸé—´æ°”é“ä¸Šçš®JAK-STATä¿¡å·è¿‡åº¦æ¿€æ´»ä¼šæŸå®³IIIå‹å¹²æ‰°ç´ ååº”[å•ç»†èƒRNAæµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE253973" target="_blank" rel="noopener noreferrer">GSE253973 é—´çš®ç˜¤ä¸­çš„æˆçº¤ç»´ç»†èƒæ ·ç»†èƒå¯èƒ½æ¥æºäºè‚¿ç˜¤ç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE220752" target="_blank" rel="noopener noreferrer">GSE220752 Hyal1åŸºå› æ•²é™¤å°é¼ è‚è„ç»„ç»‡çš„è½¬å½•ç»„</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-12 21:35</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>